PMID- 16817784
OWN - NLM
STAT- MEDLINE
DCOM- 20061128
LR  - 20151119
IS  - 1744-9979 (Print)
IS  - 1744-9979 (Linking)
VI  - 10
IP  - 3
DP  - 2006 Jun
TI  - LDL-apheresis reduces P-Selectin, CRP and fibrinogen -- possible important 
      implications for improving atherosclerosis.
PG  - 219-23
AB  - Although it is known that LDL-apheresis improves coronary artery stenosis (CAS) 
      as well as ischemic limbs seen in patients with peripheral arterial occlusive 
      disease (PAOD), the underlying mechanisms remain still unknown. LDL-apheresis 
      might exert its favorable action through anti-inflammatory effects. We studied 
      whether or not serum or plasma levels of P-selectin, high sensitivity C-reactive 
      protein (hsCRP), monocyte chemoattractant protein-1 (MCP-1) or fibrinogen could 
      be reduced in patients with PAOD before and after 10 sessions of LDL-apheresis. 
      Sixteen patients (12 patients with hemodialysis, HD) with PAOD were enrolled in 
      the present study. LDL-apheresis was carried out 10 times (treated plasma of 3000 
      mL) over 5 weeks. Serum levels of P-selectin were significantly reduced from 516 
      +/- 153 to 290 +/- 52 ng/mL before and after 10-sessions of LDL-apheresis, 
      respectively (P < 0.05). Likewise, serum levels of hsCRP decreased from 9.118 +/- 
      2.649 to 5.587 +/- 2.445 mg/L (P < 0.01); and plasma fibrinogen levels 
      statistically decreased from 196 +/- 9.82 to 149 +/- 7.97 mg/dL (P < 0.01), 
      whereas serum levels of MCP-1 were not significantly changed. The favorable 
      actions of LDL-apheresis might include anti-inflammatory effects, which could 
      lead to an improvement of CAS and PAOD. Moreover, this intervention might be 
      applicable for patients with atherosclerotic cardiovascular disorders, 
      particularly in patients with HD.
FAU - Kobayashi, Shuzo
AU  - Kobayashi S
AD  - Shonan Kamakura General Hospital, Department of Nephrology and Kidney & Dialysis 
      Center, Yamazaki Kamakura, Japan. shuzo@shonankamakura.or.jp
FAU - Oka, Machiko
AU  - Oka M
FAU - Moriya, Hidekazkeu
AU  - Moriya H
FAU - Maesato, Kyoko
AU  - Maesato K
FAU - Okamoto, Koji
AU  - Okamoto K
FAU - Ohtake, Takayasu
AU  - Ohtake T
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - Australia
TA  - Ther Apher Dial
JT  - Therapeutic apheresis and dialysis : official peer-reviewed journal of the 
      International Society for Apheresis, the Japanese Society for Apheresis, the 
      Japanese Society for Dialysis Therapy
JID - 101181252
RN  - 0 (Biomarkers)
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (P-Selectin)
RN  - 9001-32-5 (Fibrinogen)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arterial Occlusive Diseases/*therapy
MH  - Atherosclerosis/*therapy
MH  - Biomarkers/blood
MH  - Blood Component Removal/*methods
MH  - C-Reactive Protein/analysis
MH  - Coronary Stenosis/*therapy
MH  - Female
MH  - Fibrinogen/analysis
MH  - Hemoperfusion/*methods
MH  - Humans
MH  - Lipoproteins, LDL/*blood/isolation & purification
MH  - Male
MH  - Middle Aged
MH  - P-Selectin/blood
MH  - Statistics, Nonparametric
MH  - Treatment Outcome
EDAT- 2006/07/05 09:00
MHDA- 2006/12/09 09:00
CRDT- 2006/07/05 09:00
PHST- 2006/07/05 09:00 [pubmed]
PHST- 2006/12/09 09:00 [medline]
PHST- 2006/07/05 09:00 [entrez]
AID - TAP332 [pii]
AID - 10.1111/j.1744-9987.2006.00332.x [doi]
PST - ppublish
SO  - Ther Apher Dial. 2006 Jun;10(3):219-23. doi: 10.1111/j.1744-9987.2006.00332.x.